This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
by Kinjel Shah
Pipeline success, cost-cutting measures, share buybacks, product launches, ramped up M&A and collaboration activities should keep the sector afloat, going forward.
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
by Zacks Equity Research
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Infinity Inks Deal With Roche for Phase II Study of IPI-549
by Zacks Equity Research
Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
by Zacks Equity Research
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
J&J Seeks Approval for Darzalex in Expanded Patient Group
by Zacks Equity Research
J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.
Celgene (CELG) Submits Application for MS Drug in Europe
by Zacks Equity Research
Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.
Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
by Zacks Equity Research
Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.
Bayer Submits Application in EU for Prostate Cancer Drug
by Zacks Equity Research
Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Is Bristol-Myers (BMY) a Solid Pick for Value Investors?
by Zacks Equity Research
Let's see if Bristol-Myers (BMY) stock is a good choice for value-oriented investors right now from multiple angles.
Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Top Analyst Reports for Boeing, Abbott & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Abbott (ABT) and PayPal (PYPL).
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.
Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.
Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover
by Zacks Equity Research
Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.
Why Is Bristol-Myers (BMY) Up 4% Since Last Earnings Report?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck to Buy Immunotherapy Developer Immune Design for $300M
by Zacks Equity Research
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
by Zacks Equity Research
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
How to Replicate Hedge Fund Strategies with ETFs
by Neena Mishra
Liquid alternative ETFs provide access to hedge fund strategies that are not correlated with major asset classes.
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
by Zacks Equity Research
Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.